

**Acknowledgment and Consent for Disclosure of  
Section 712(c)(2)(B) of the Federal Food, Drug, and Cosmetic Act  
and 18 U.S.C. §208 (b) Particular Matter Waiver**

**Name:** Andrew Leon, Ph.D.  
**Committee:** Psychopharmacologic Drugs Advisory Committee  
**Meeting Date:** February 6, 2008

I acknowledge that contingent upon public disclosure of the following financial interest submitted on my FDA Form 3410 and related to the agenda item: NDA 22-173 Zyprexa Adhera (olanzapine pamoate depot) long acting intramuscular (IM) injection 210mg, 300mg, and 405 mg per/vial, sponsored by Eli Lilly & Company, for treatment of schizophrenia,, I am eligible to receive a particular matter waiver under Section 712(c)(2)(B) and 18 U.S.C. §208.

<b>Type of Interest</b>	<b>Nature</b>	<b>Magnitude</b>
Member of a DSMB for a competing product	Competitor	Between \$10,000 and \$50,000 per year
Member of a DSMB for a competing product	Competitor	Less than \$10,000 per year
Member of a DSMB for unrelated matter	Competitor	Between \$10,000 and \$50,000 per year

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading the statement into the record at the time of the meeting. I understand that without public disclosure of these interests the waivers are not valid.

\_\_\_\_\_  
/S/  
Signature of SGE

\_\_\_\_\_  
1/3/08  
Date